Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drug for prevention and/or therapy of endometriosis

a technology for endometriosis and endometriosis, applied in the direction of drug compositions, biocide, heterocyclic compound active ingredients, etc., can solve the problem of not having a complete treatmen

Inactive Publication Date: 2009-09-10
SUGAMATA MASAO
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0006]That is, the present invention provides a drug for prevention and / or therapy of endometriosis comprising an antiallergic agent as an effective ingredient. The present invention also provides a use of an antiallergic agent for the production of a drug for prevention and / or therapy of endometriosis. The present invention further provides a method for prevention and / or therapy of endometriosis comprising administering an antiallergic agent to a patient suffering from endometriosis, in an amount effective for the prevention or therapy of endometriosis.

Problems solved by technology

However, these therapies are symptomatic treatments, and no complete therapy exists.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

reference example 1

[0017]Observation of Human Endometriosis Specimens

[0018]Adhered lesions in pelvic cavity were sampled from patients suffering from endometriosis (external endometriosis), and stained by hematoxylin-eosin staining or toluidine blue staining according to the conventional methods, followed by observation of the stained samples with an light microscope. The magnification was 10× when observing the hematoxylin-eosin-stained specimens, and 20× or 100×when observing the toluidine blue-stained specimens. The tissue was also subjected to uranium-lead double staining according to the conventional method, and the obtained specimens were observed with an electron microscope at a magnification of 3000× to 5000×.

[0019]As a result, in the toluidine blue-stained specimens of the tissues from patients suffering from endometriosis, invasion of mast cells was observed. Further, by the observation with the electron microscope, degranulation of mast cells was observed in addition to the invasion of the ...

example 1

Therapeutic Effect by Administration of Epinastine Hydrochloride

[0023]Endometriosis model rats were prepared by the same method as in Comparative Example 1. From 24 hours after the preparation of the endometriosis model rats, an antiallergic agent (trademark “Alesion Tablet” produced by Boehringer Ingelheim) containing epinastine hydrochloride as the active component was orally administered to the rats for 6 days at a dose of 0.04 mg / kg bodyweight per day in terms of epinastine hydrochloride. Seven days after the preparation of the model rats, at which the model lesion reached its peak, the peritoneum tissues including the graft up to the abdominal muscle were excised to obtain lesion samples. The obtained pathological samples were stained as in Reference Example 1, and the resultants were observed with an light microscope and with an electron microscope.

[0024]As a result, the invasion of mast cells was apparently reduced when compared with the case of Comparative Example 1. By the ...

example 2

Therapeutic Effect by Administration of Ketotifen Fumarate

[0025]The same procedures as in Example 1 were repeated except that an antiallergic agent containing ketotifen fumarate as the active component (trademark “Zaditen” produced by Ciba-Geigy Japan Limited) was administered in place of the antiallergic agent containing epinastine hydrochloride as an active component.

[0026]As a result, the invasion of mast cells was apparently reduced when compared with the case of Comparative Example 1. By the observations with the light microscope and with the electron microscope, apoptosis of fibroblast cells was observed, and prominent inhibition of proliferation of the interstitial cells by the induction of apoptosis of interstitial cells, especially fibroblast cells was observed. From these, it was proved that ketofetin is effective for the therapy of endometriosis.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
light microscopeaaaaaaaaaa
electron microscopeaaaaaaaaaa
Login to View More

Abstract

A drug effective for prevention and therapy of endometriosis is disclosed. The drug for prevention and / or therapy of endometriosis according to the present invention comprises an antiallergic agent as an effective ingredient.

Description

[0001]This application is a Continuation of U.S. application Ser. No. 10 / 450,954, filed on Jun. 18, 2003, which is the national phase of PCT International Application No. PCT / JP01 / 11069 which has an International filing date of Dec. 18, 2001 which designated the United States and which claims priority to Japanese Application 2000 / 383224 filed on Dec. 18, 2000. The entire contents of the above applications are hereby incorporated by reference.TECHNICAL FIELD[0002]The present invention relates to a drug for prevention and / or therapy of endometriosis.BACKGROUND ART[0003]Endometriosis is a disease wherein endometrium or endometrium-like tissue ectopically proliferates at a site other than the inner surface of the cavity of uterus which is the natural site thereof. The cause of endometriosis is unknown, and therapies such as separation of the adhered tissues by surgery, administration of hormones and administration of analgesics are performed. However, these therapies are symptomatic tre...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/55A61K31/4535A61K31/41A61P43/00A61K45/00A61K31/437A61K31/4436A61K31/551A61P15/00
CPCA61K31/41A61K31/551A61K31/55A61K31/4535A61P15/00A61P43/00
Inventor SUGAMATA, MASAO
Owner SUGAMATA MASAO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com